Posts

Showing posts from August, 2026

Eye Drop Manufacturing Process Explained: Why It Matters Before You Choose a Manufacturer

  Most brand owners shopping for an eye drop manufacturer skim past the actual production process and jump straight to price per unit. That's a mistake specific to ophthalmic products: a formulation destined for direct contact with eye tissue carries a higher sterility bar than almost any other pharmaceutical category, and the manufacturing process itself is exactly where that sterility either gets protected or compromised. Understanding the real eye drop manufacturing process — not the marketing summary of it — is the single best filter for telling a genuinely capable partner apart from one cutting corners. This piece walks through what actually happens on a compliant ophthalmic production line, what it costs to build that capability in-house versus outsourcing it, and where Pushkar Pharma fits into that comparison. What the Eye Drop Manufacturing Process Actually Involves A compliant WHO-GMP ophthalmic production line runs through a fairly consistent sequence, regardless of whic...

Launching Your Own Injectable Brand in India: The Real Process, Costs, and Mistakes First-Timers Make

  Most guides on injectable manufacturing stop at "check the WHO-GMP certificate and pick a good partner." That's true, but it's also the easy 20% of the decision. The part nobody walks you through is what actually happens between signing with a manufacturer and getting a saleable batch of vials into a distributor's hands — the dosage-form choice, the real cost range, and the mistakes that quietly eat a first-timer's margin. This is written for the pharma entrepreneur or distributor who's already decided injectables are the segment to enter and now needs to know what the process genuinely looks like. Why Injectables Aren't Just "Tablets, But Liquid" Sterile dosage forms carry a different risk profile than oral solids, and that changes everything about how you plan the launch. A contaminated tablet batch is a quality failure. A contaminated injectable batch is a direct route into someone's bloodstream — which is why aseptic filling, cleanr...

Top 10 Injection Manufacturing Companies in India: Where Does Your Supplier Rank?

 India's injectables market is now worth over ₹1,50,000 crore, and demand for sterile liquid injections, vaccines, and hospital formulations keeps climbing. But not every manufacturer can back that growth with real compliance and consistent quality. Our latest blog breaks down the top 10 injection manufacturing companies in India for 2026 — from third-party manufacturers like Pushkar Pharma to industry giants like Cipla, Sun Pharma, Lupin, and Serum Institute of India. Each entry covers their product range, certifications (WHO-GMP, US-FDA, EU-GMP), and what actually sets them apart, whether that's robotic sterile filling lines, R&D investment, or export-ready compliance. We also cover what to check before signing with any injectable manufacturer: regulatory certifications, cleanroom infrastructure, capital investment (typically ₹10–50 lakh), and how wide their product portfolio really is. If you're a distributor, hospital procurement lead, or entrepreneur evaluating ...

Injection Manufacturing Companies in India: What "Top 10" Lists Usually Leave Out

  India now supplies roughly 40% of the injectable generics used in the United States — a scale that makes the country one of the world's largest sources of sterile injectable medicine, not just a low-cost manufacturing hub. That scale is also why "top injection manufacturing companies in India" searches return dozens of competing lists, most written by the manufacturers featured on them. None of that makes the underlying question less important: how do you actually tell a capable, compliant injection manufacturing company apart from one that just has a well-designed website? This piece looks at how big India's injectable segment actually is, what separates a genuinely reliable third-party injection manufacturer from a listicle entry, and where a company like Pushkar Pharma fits into that comparison. How Big Is India's Injectable Manufacturing Segment? India's generic injectables market was valued at roughly USD 3.0 billion in 2024 and is projected to reach ...